← Leaderboards
Ramaprasad Srinivasan
Division Of Basic Sciences - Nci
$623,093
Attributed
$1,869,279
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $649.8K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$1,869,279 · 1
By mechanism
U01$1,869,279 · 1
Top collaborators
- Marston Linehan4 shared
- David Mcdermott4 shared
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Vascular Endothelial Growth Factors”
- Anthony J St Leger · University Of Pittsburgh At Pittsburgh$5,632,093
- Eliza C Miller · Columbia University Health Sciences$4,989,243
- Fabrice Dabertrand · University Of Colorado Denver$4,578,475
- Suchismita Acharya · Ayuvis Research, Inc.$4,247,453
- Ye Sun · Boston Children'S Hospital$4,181,435
- Sana D Karam · University Of Colorado Denver$4,039,397
Research focus
Vascular Endothelial Growth FactorsTumorRenal CarcinomaMalignant NeoplasmsPathway InteractionsRenal Cell CarcinomaClinical TrialsClear CellResponsePhase 2 StudyDesignAccountingTargeted AgentNovel StrategiesSystemic TherapyBaseEvaluationKidney NeoplasmsOperative Surgical ProceduresMolecularPublishingCollaborationsPre-ClinicalPreclinical Study
Grant awards (22)
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,842,541
ZIA · FY2025 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$789,660
ZIA · FY2025 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,603,147
ZIA · FY2024 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$687,063
ZIA · FY2024 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,471,018
ZIA · FY2023 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$630,437
ZIA · FY2023 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,437,228
ZIA · FY2022 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$615,955
ZIA · FY2022 · CA · contact PI
Developing a Translation Pipeline for VHL Mutant Malignancies$400,168
U01 · FY2022 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,048,777
ZIA · FY2021 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$449,476
ZIA · FY2021 · CA · contact PI
Developing a Translation Pipeline for VHL Mutant Malignancies$408,334
U01 · FY2021 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$1,179,894
ZIA · FY2020 · CA · contact PI
Novel Approaches to Targeting Cancers Associated with VHL Mutations$505,669
ZIA · FY2020 · CA · contact PI
Developing a Translation Pipeline for VHL Mutant Malignancies$410,974
U01 · FY2020 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$885,117
ZIA · FY2019 · CA · contact PI
Developing a Translation Pipeline for VHL Mutant Malignancies$649,803
U01 · FY2019 · CA
Novel Approaches to Targeting Cancers Associated with VHL Mutations$379,337
ZIA · FY2019 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$774,077
ZIA · FY2018 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$741,917
ZIA · FY2017 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$683,784
ZIA · FY2016 · CA · contact PI
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC$491,885
ZIA · FY2015 · CA · contact PI